Immunization with PCEP microparticles containing pertussis toxoid, CpG ODN and a synthetic innate defense regulator peptide induces protective immunity against pertussis

Vaccine

Volumn 29, Issue 38, 2011, Pages 6540-6548

  Garlapati, Srinivas ^a   Eng, Nelson F ^a   Kiros, Tadele G ^a   Kindrachuk, Jason ^b   Mutwiri, George K ^a   Hancock, Robert E W ^b   Halperin, Scott A ^e   Potter, Andrew A ^a   Babiuk, Lorne A ^c   Gerdts, Volker ^a,d  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIVERSITY OF SASKATCHEWAN   (Canada)

^e DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Adjuvants; CpG; Innate defense regulator peptide; Pertussis vaccine; Polyphosphazene

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; INNATE DEFENSE REGULATOR PEPTIDE; INTERLEUKIN 12; INTERLEUKIN 17; MONOCYTE CHEMOTACTIC PROTEIN 1; PEPTIDE DERIVATIVE; PERTUSSIS TOXIN; POLYPHOSPHAZENE; QUADRACEL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG FORMULATION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; IMMUNOMODULATION; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PERTUSSIS; PRIORITY JOURNAL; SINGLE DRUG DOSE; SPLEEN CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; BACTERIAL LOAD; CYTOKINES; DISEASE MODELS, ANIMAL; DRUG CARRIERS; FEMALE; LUNG; LYMPHOCYTES; MACROPHAGES; MICE; MICE, INBRED BALB C; MICROSPHERES; OLIGODEOXYRIBONUCLEOTIDES; PERTUSSIS VACCINE; PHENYLPROPIONATES; POLYMERS; RODENT DISEASES; SPLEEN; TOXOIDS; WHOOPING COUGH;

EID: 80051669229     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.009     Document Type: Article

References (27)

1. Bode C., Zhao G., Steinhagen F., Kinjo T., Klinman D.M. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 2011, 10(4):499-511.
2. Pulendran B., Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell 2006, 124(4):849-863.
3. Joseph A., Louria-Hayon I., Plis-Finarov A., Zeira E., Zakay-Rones Z., Raz E., et al. Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines. Vaccine 2002, 20(27-28):3342-3354.
4. Zaks K., Jordan M., Guth A., Sellins K., Kedl R., Izzo A., et al. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J Immunol 2006, 176(12):7335-7345.
5. Mullen G.E., Aebig J.A., Dobrescu G., Rausch K., Lambert L., Long C.A., et al. Enhanced antibody production in mice to the malaria antigen AMA1 by CPG 7909 requires physical association of CpG and antigen. Vaccine 2007, 25(29):5343-5347.
6. Qian F., Rausch K.M., Muratova O., Zhou H., Song G., Diouf A., et al. Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders. Vaccine 2008, 26(20):2521-2527.
7. Bowdish D.M., Davidson D.J., Scott M.G., Hancock R.E. Immunomodulatory activities of small host defense peptides. Antimicrob Agents Chemother 2005, 49(5):1727-1732.
8. Scott M.G., Davidson D.J., Gold M.R., Bowdish D., Hancock R.E. The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. J Immunol 2002, 169(7):3883-3891.
9. Cao D., Li H., Jiang Z., Cheng Q., Yang Z., Xu C., et al. CpG oligodeoxynucleotide synergizes innate defense regulator peptide for enhancing the systemic and mucosal immune responses to pseudorabies attenuated virus vaccine in piglets in vivo. Int Immunopharmacol 2011, 11(6):748-754.
10. Cao D., Li H., Jiang Z., Xu C., Cheng Q., Yang Z., et al. Synthetic innate defence regulator peptide enhances in vivo immunostimulatory effects of CpG-ODN in newborn piglets. Vaccine 2010, 28(37):6006-6013.
11. Kindrachuk J., Jenssen H., Elliott M., Townsend R., Nijnik A., Lee S.F., et al. A novel vaccine adjuvant comprised of a synthetic innate defence regulator peptide and CpG oligonucleotide links innate and adaptive immunity. Vaccine 2009, 27(34):4662-4671.
12. Garlapati S., Eng N.F., Wilson H.L., Buchanan R., Mutwiri G.K., Babiuk L.A., et al. PCPP (poly[di(carboxylatophenoxy)-phosphazene]) microparticles co-encapsulating ovalbumin and CpG oligo-deoxynucleotides are potent enhancers of antigen specific Th1 immune responses in mice. Vaccine 2010, 28(52):8306-8314.
13. Kovacs-Nolan J., Mapletoft J.W., Lawman Z., Babiuk L.A., van Drunen Littel-van den Hurk S. Formulation of bovine respiratory syncytial virus fusion protein with CpG oligodeoxynucleotide, cationic host defence peptide and polyphosphazene enhances humoral and cellular responses and induces a protective type 1 immune response in mice. J Gen Virol 2009, 90(Pt 8):1892-1905.
14. Chan G.J., Moulton L.H., Becker S., Munoz A., Black R.E. Non-specific effects of diphtheria tetanus pertussis vaccination on child mortality in Cebu, The Philippines. Int J Epidemiol 2007, 36(5):1022-1029.
15. Eldridge J.H., Staas J.K., Meulbroek J.A., Tice T.R., Gilley R.M. Biodegradable and biocompatible poly(dl-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect Immun 1991, 59(9):2978-2986.
16. Xiang S.D., Scholzen A., Minigo G., David C., Apostolopoulos V., Mottram P.L., et al. Pathogen recognition and development of particulate vaccines: does size matter?. Methods 2006, 40(1):1-9.
17. Lee J.G., Lee S.H., Park D.W., Yoon H.S., Chin B.R., Kim J.H., et al. Toll-like receptor 9-stimulated monocyte chemoattractant protein-1 is mediated via JNK-cytosolic phospholipase A2-ROS signaling. Cell Signal 2008, 20(1):105-111.
18. Higgins S.C., Jarnicki A.G., Lavelle E.C., Mills K.H. TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells. J Immunol 2006, 177(11):7980-7989.
19. Mills K.H., Induction function and regulation of IL-17-producing T cells. Eur J Immunol 2008, 38(10):2636-2649.
20. Moore A., McGuirk P., Adams S., Jones W.C., McGee J.P., O'Hagan D.T., et al. Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells. Vaccine 1995, 13(18):1741-1749.
21. Andrianov A.K., Chen J., Payne L.G. Preparation of hydrogel microspheres by coacervation of aqueous polyphosphazene solutions. Biomaterials 1998, 19(1-3):109-115.
22. Andrianov A.K. Polymeric drugs drug delivery systems. IDrugs 1998, 1(7):767-768.
23. Mills K.H., Ryan M., Ryan E., Mahon B.P. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect Immun 1998, 66(2):594-602.
24. Mills K.H., Barnard A., Watkins J., Redhead K. Cell-mediated immunity to Bordetella pertussis: role of Th1 cells in bacterial clearance in a murine respiratory infection model. Infect Immun 1993, 61(2):399-410.
25. Giuliano M., Mastrantonio P., Giammanco A., Piscitelli A., Salmaso S., Wassilak S.G. Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. J Pediatr 1998, 132(6):983-988.
26. Hellwig S.M., van Spriel A.B., Schellekens J.F., Mooi F.R., van de Winkel J.G. Immunoglobulin A-mediated protection against Bordetella pertussis infection. Infect Immun 2001, 69(8):4846-4850.
27. Reljic R. In search of the elusive mouse macrophage Fc-alpha receptor. Immunol Lett 2006, 107(1):80-81.